GRAL
GRAIL is a healthcare company focused on detecting cancer earlier using blood-based multi-cancer early detection tests. It develops the Galleri Test and leverages next-generation sequencing, population-scale clinical studies, and advanced data analysis to identify cancer signals before symptoms appear. The company aims to alleviate the global burden of cancer with a mission-driven approach and operates with a focus on early detection across diverse populations in the United States and beyond.
No recent deals for this company.